Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer June 8, 2026 8:00 AM EDT
Company Participants
Elizabeth Hickin
Malte Peters – President, CEO & Director
Adam Crystal – President of Research & Development
Matthew Gall – Chief Financial Officer
Conference Call Participants
Brian Wolpin
Eric Schmidt – Cantor Fitzgerald & Co., Research Division
Michael Schmidt – Guggenheim Securities, LLC, Research Division
Laura Prendergast – Stifel, Nicolaus & Company, Incorporated, Research Division
Kelsey Goodwin – Piper Sandler & Co., Research Division
Joseph Catanzaro – Mizuho Securities USA LLC, Research Division
Andrew Berens – Leerink Partners LLC, Research Division
John Newman – Canaccord Genuity Corp., Research Division
Maurice Raycroft – Jefferies LLC, Research Division
Yuan Zhi – B. Riley Securities, Inc., Research Division
Kalpit Patel – Wolfe Research, LLC
Robert Driscoll – Wedbush Securities Inc., Research Division
Presentation
Operator
Good day, and welcome to the Tango Therapeutics conference call. [Operator Instructions] Please note, this call is being recorded. I’d now like to turn the call over to Liz Hickin, Vice President, Investor Relations and Corporate Communications. Please go ahead.
Elizabeth Hickin
Thank you, and good morning, everyone, and thank you for joining us on today’s call. This morning, we issued a press release on the data, which can be found on the Investors and Media section of our website, www.tangotx.com. Before we begin, let me review our safe harbor statement. We will be making forward-looking statements on this call that are subject to risks and uncertainties discussed in detail in today’s press release and in our filings with the Securities and Exchange Commission. This call is being recorded, and a replay will be available on our website.
The agenda for this morning’s call is as follows: Malte Peters, Tango’s President and CEO, will share some introductory remarks. We are pleased to be joined today by Dr. Brian Wolpin, Director
You must be logged in to post a comment Login